Technical Analysis for IDRA - Idera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.1 1.85% 0.02
IDRA closed up 1.85 percent on Friday, April 16, 2021, on 66 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical IDRA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.85%
Narrow Range Bar Range Contraction 1.85%
New 52 Week Low Weakness 1.85%
Wide Bands Range Expansion 1.85%
Down 3 Days in a Row Weakness 1.85%
Down 4 Days in a Row Weakness 1.85%
Older End-of-Day Signals for IDRA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% 1 day ago
Up 2% 1 day ago
Up 1% 1 day ago
60 Minute Opening Range Breakout 1 day ago
Down 5% 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Idera Pharmaceuticals, Inc. Description

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its autoimmune and inflammatory disease programs include IMO-3100, an antagonist of TLR7 and TLR9, which has completed Phase II clinical trials for the treatment of psoriasis; and IMO-8400, an antagonist of TLR7, TLR8, and TLR9 that is in Phase I clinical trials for the treatment of psoriasis/lupus. The company's cancer program comprises IMO-2055, which has completed Phase Ib clinical trials for treatment of non-small cell lung cancer; and has completed Phase II clinical trials for the treatment of squamous cell, head and neck, and colorectal cancer. It is also developing IMO-2134 that has completed Phase I clinical trials to treat asthma and allergy. In addition, the company's research candidates include IMO-4200 for hematologic malignancies; and TLR3 Agonists for infectious diseases and other applications, as well as gene silencing oligonucleotides for inhibition of gene expression by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to research, develop, and commercialize vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Infectious Diseases Treatment Of Cancer Genetics Small Cell Lung Cancer Clinical Trial Non Small Cell Lung Cancer Alzheimer's Disease Inflammatory Disease Inflammatory Diseases Asthma Gene Expression Psoriasis Allergy Colorectal Cancer Hematologic Malignancies Immune Response Oligonucleotide Autoimmune And Inflammatory Diseases Autoimmune And Inflammatory Disease Lupus RNA Treatment Of Non Small Cell Lung Cancer Nucleotides Gene Silencing United Nations Tlr7 Tlr9 Treatment Of Psoriasis Vaccine Products Tlr8

Is IDRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.12
52 Week Low 1.01
Average Volume 3,443,811
200-Day Moving Average 3.16
50-Day Moving Average 3.47
20-Day Moving Average 1.36
10-Day Moving Average 1.24
Average True Range 0.27
ADX 33.08
+DI 17.36
-DI 40.30
Chandelier Exit (Long, 3 ATRs ) 5.02
Chandelier Exit (Short, 3 ATRs ) 1.82
Upper Bollinger Band 1.78
Lower Bollinger Band 0.94
Percent B (%b) 0.19
BandWidth 62.09
MACD Line -0.70
MACD Signal Line -0.78
MACD Histogram 0.078
Fundamentals Value
Market Cap 38.72 Million
Num Shares 35.2 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -0.66
Price-to-Sales 42.09
Price-to-Book 1.24
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.28
Resistance 3 (R3) 1.27 1.20 1.25
Resistance 2 (R2) 1.20 1.15 1.21 1.24
Resistance 1 (R1) 1.15 1.13 1.18 1.16 1.23
Pivot Point 1.08 1.08 1.09 1.09 1.08
Support 1 (S1) 1.03 1.03 1.06 1.04 0.97
Support 2 (S2) 0.96 1.01 0.97 0.96
Support 3 (S3) 0.91 0.96 0.95
Support 4 (S4) 0.92